<DOC>
	<DOC>NCT00317369</DOC>
	<brief_summary>The purpose of this study to examine the safety and efficacy of OPC-6535 and determine its optimal dose by once-daily oral administration at 0, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic acid (5-ASA) or in combination with a fixed oral dose of 5-ASA and enteral nutrition in patients with active Crohn's disease.</brief_summary>
	<brief_title>A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patients with active Crohn's disease Patients who have a primary lesion in either the small intestine or the large intestine Patients who have been receiving an oral 5ASA formulation at a fixed regimen and at a fixed dose Patients who have either never received enteral nutrition or have been receiving enteral nutrition at a fixed intake of 1200 kcal/day or less Either inpatient or outpatient Patients who have an external fistula (including anal fistula) in which persistent drainage is observed (and who require treatment with antibiotics or synthetic antibacterial agents) Patients with short bowel syndrome (and who require intravenous nutritional support due to insufficient intestinal nutrient uptake) Patients with an artificial anus Patients who have a complication of serious infectious disease (intraabdominal abscess, etc.) Patients who have a complication of malignant tumor Female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the study period</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>OPC-6535</keyword>
	<keyword>Crohn's disease</keyword>
</DOC>